Cathie Wood’s ARK Invest Shifts Focus to Biotech, Trims Tech and Gaming Holdings

Cathie Wood's ARK Invest executed significant portfolio adjustments on August 26, 2025, channeling over $11 million into gene-editing biotech stocks while reducing exposure to streaming and gaming companies. The MOVE signals a strategic pivot toward disruptive healthcare technologies.

ARK Innovation ETF (ARKK) acquired $8.98 million worth of CRISPR Therapeutics (CRSP) shares, following a $10.26 million purchase just days prior. The fund simultaneously bolstered its position in Intellia Therapeutics (NTLA) with $2.18 million in fresh investments, building on a $3.78 million position established earlier in the week.

Concurrently, ARK systematically reduced stakes in Roku (ROKU) and DraftKings (DKNG), continuing a gradual exit from consumer-facing tech platforms. The reallocation reflects Wood's conviction in precision medicine's growth potential amid shifting market dynamics.